Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 16/20 | 0.46 |
| ▸ | PDE5A | O76074 | 1/20 | 0.40 |
| ▸ | PDE1A | P54750 | 2/20 | 0.36 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.36 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL471102 | 0.96 | PDE9A (0.43) | PDE9APDE5A | |
| SCHEMBL15103379 | 0.91 | PDE9A (0.46) | PDE9APDE5APDE1APDE1BPDE1C | |
| SCHEMBL7904323 | 0.91 | PDE9A (0.44) | PDE9APDE5APDE1APDE1BPDE1C | |
| SCHEMBL12044905 | 0.90 | PDE9A (0.47) | PDE9APDE5APDE1APDE1BPDE1C | |
| SCHEMBL1723624 | 0.89 | PDE9A (0.43) | PDE9APDE5APDE1APDE1B | |
| SCHEMBL15103321 | 0.89 | PDE9A (0.43) | PDE9APDE5APDE1B | |
| SCHEMBL12044687 | 0.89 | PDE9A (0.43) | PDE9APDE5APDE1B | |
| SCHEMBL15109423 | 0.88 | PDE9A (0.45) | PDE9APDE5A | |
| SCHEMBL15109406 | 0.88 | PDE9A (0.42) | PDE9APDE5APDE1B | |
| SCHEMBL10053410 | 0.88 | PDE9A (0.43) | PDE9APDE5APDE1APDE1BPDE1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8901126-B2 | Substituted imidazo[1,5-A]quinoxalin-4-ones are useful for preventing or treating storage dysfunction, voiding dysfunction and bladder/urethral diseases | ASTELLAS PHARMA INC. (JP) | 2014-12-02 | — | — | US | disclosed |
| US-8901126-B2 | Substituted imidazo[1,5-A]quinoxalin-4-ones are useful for preventing or treating storage dysfunction, voiding dysfunction and bladder/urethral diseases | ASTELLAS PHARMA INC. (JP) | 2014-12-02 | — | — | US | disclosed |
| US-8901126-B2 | Substituted imidazo[1,5-A]quinoxalin-4-ones are useful for preventing or treating storage dysfunction, voiding dysfunction and bladder/urethral diseases | ASTELLAS PHARMA INC. (JP) | 2014-12-02 | — | — | US | disclosed |
| US-20130296329-A1 | QUINOXALINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-11-07 | — | — | US | disclosed |
| US-20130296329-A1 | QUINOXALINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-11-07 | — | — | US | disclosed |
| US-20130296329-A1 | QUINOXALINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-11-07 | — | — | US | disclosed |
| EP-2615096-A1 | QUINOXALINE COMPOUND | Astellas Pharma Inc. (JP) | 2013-07-17 | — | — | EP | disclosed |
| WO-2012033101-A1 | QUINOXALINE COMPOUND | アステラス製薬株式会社 (JP) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296329-A1 | QUINOXALINE COMPOUND | PDE9A, PDE5A, PDE2A | PDE9A 1/4885PDE5A 2/4885PDE1A 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.